Celularity (CELU) announced that it has received a letter from the Listing Qualifications department of the Nasdaq Stock Market, confirming that Celularity has regained compliance with Nasdaq Listing Rule 5250(c)(1). Following the filing of its Quarterly Report on Form 10-Q for the period ended September 30, 2024, Nasdaq has determined that the matter is now closed. “We are pleased to have fully addressed Nasdaq’s requirements and resolved this matter, ensuring that our stock remains listed and continues to trade on the Nasdaq Capital Market,” said Robert Hariri, M.D., Ph.D., Founder, Chairman, and CEO of Celularity. “This milestone reflects our commitment to regulatory compliance and transparency. The significant improvements we’ve made to our financial reporting infrastructure will serve as a strong foundation for our future growth and success.”
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELU:
- Morning Movers: Lululemon, Ulta jump following quarterly reports
- Celularity reports Q3 EPS (73c) vs. ($4.98) last year
- Celularity receives Nasdaq listing non-compliance notice
- Celularity strategic partner announces stem cell, regenerative medicine center
- Celularity resolves Nasdaq listing compliance issue